Team
Portfolio
News
Contact

Back to Portfolio

Kartos Therapeutics

Website LinkedIn

Clinical stage company developing a MDM2 inhibitor- Navtemadlin- for the treatment of myelofibrosis

Therapeutic Area
Oncology: Stage
Clinical: CEO
Jesse McGreivy, MD: Geography
Redwood City, USA

© 2024 SR One Capital ManagementLinkedIn

For media enquires, please email sronemedia@sambrown.com

California

929 Main Street
Suite 200
Redwood City, CA 94063
United States

Pennsylvania

985 Old Eagle School Road
Suite 511
Wayne, PA 19087
United States

London

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom

Privacy Policy Terms & Conditions Regulatory Disclosures